Background Falls are a frequent and serious complication of Parkinson's disease and are related partly to an underlying cholinergic defi cit that contributes to gait and cognitive dysfunction in these patients. Gait dysfunction can lead to an increased variability of gait from one step to another, raising the likelihood of falls. In the ReSPonD trial we aimed to assess whether ameliorating this cholinergic defi cit with the acetylcholinesterase inhibitor rivastigmine would reduce gait variability.
Introduction
Falls are a common and devastating event in individuals with Parkinson's disease. Prospective studies report that 70% of people with Parkinson's disease have at least one fall in a year and 39% fall recurrently; 1 median survival in patients that have recurrent falls is 6 years. 2 Even in those who have not previously fallen, 21% will fall in the next 3 months. 3 Consequences of falls include fractures and injury, 4 fear of future falls, 5 hospital admission, 6 and increased caregiver burden, 7 with falls cited as one of the worst aspects of the disease. 8 Despite increased understanding of the pathophysiology that underlies risk of falls, few effi cacious interventions are available. There is therefore an urgent and unmet need to identify eff ective treatment strategies.
Parkinson's disease is associated with slowing of gait due to reductions in step length 9 and a loss of gait automaticity, manifesting as increased gait variability. [9] [10] [11] Increased gait variability refl ects impaired neural control of gait, in which large variation from one step to the next results in a highly unstable gait and falls become more likely. Therefore, gait variability serves as a marker of fall risk in individuals with Parkinson's disease, as well as in those with Alzheimer's disease 12 and in older adults. 13 To compensate for the reduced gait stability, people with Parkinson's disease need additional attentional cognitive resource. 14, 15 Higher demands on attention are made when negotiating complex walking environments or when walking while undertaking concurrent cognitive tasks. When attentional demands outweigh capacity, gait performance and ability to do concurrent tasks, or both, are impaired. Dysexecutive syndrome in Parkinson's disease 16 adds to this problem in that attentional resources are inappropriately prioritised away from gait and towards concurrent tasks. 17 Postural stability is therefore compromised in situations in which concurrent motor and cognitive demands compete for limited and impaired attentional resource; consequently falls occur. 18 Dual task paradigms that explore this cognitive-motor interface have revealed strong associations between gait variability and disease severity, 14, 19 complexity of dual tasks, 20 cognitive defi cits, 19, 21 and history of falls. 10, 11, 22 An underlying loss of cholinergic function contributes to freezing 23 and other gait changes, postural instability, and cognitive dysfunction. 24 The increasing importance of the role of the brainstem pedunculopontine nucleus (PPN) in gait and falls has been shown by neuroimaging, 25, 26 lesioning, 27 and deep-brain stimulation studies. 28 Not only is Parkinson's disease associated with loss of cholinergic cell bodies in the PPN, 25 but also cholinergic output loss in the thalamus (the main target for cholinergic projection from the PPN) is greater in individuals who fall than in non-fallers. 26 Similarly, cholinergic loss in the nucleus basalis of Meynert, which projects to the cortex, 29 is purported to contribute to cognitive dysfunction in Parkinson's disease. The resultant impairment of attention aff ects the successful execution of complex motor behaviours; in rats a dual dopaminergic-cholinergic hit seems to confer propensity to falls during complex motor movement. 30 The cholinergic defi cit that contributes to gait and cognitive dysfunction in Parkinson's disease provides a rationale on which to base and target drug treatment. We hypothesised that treatment with an acetylcholinesterase inhibitor would improve gait stability and therefore prevent falls in people with Parkinson's disease. Here we aimed to assess whether this hypothesis was correct in patients that had fallen in the last year.
Methods

Study design and participants
We carried out this randomised placebo-controlled, double-blind, parallel-arm, trial at North Bristol NHS Trust Hospital, Bristol, UK. The protocol has been published previously. 31 Patients were eligible if they had moderate (Hoehn and Yahr stage 2-3) idiopathic Parkinson's disease (diagnosed by a movement disorder specialist) and had been stable (no drug adjustments needed) on antiparkinsonian drugs for 2 weeks before enrolment. Patients were taking dopaminergic drugs, along with a wide range of drugs for comorbidities.
Research in context
Evidence before this study We searched PubMed for randomised controlled trials with "Parkinson disease" and "cholinesterase inhibitors" as MeSH terms and without any language or date restrictions. We identifi ed 20 studies, of which fi ve reported a fall-related outcome. Only one randomised crossover trial sought to determine the eff ect of an acetylcholinesterase inhibitor, donepezil, on falls in Parkinson's disease (Chung et al, 2010) . In this trial, 23 patients who reported falling or near-falling more than two times a week were given donepezil or placebo for 6 weeks and then crossed over. Donepezil treatment was associated with a reduction in fall rate from 0·25 falls per day on placebo to 0·13 falls per day on donepezil (p=0·49). However, frequent fallers drove the observed benefi t and the fi nding was reported only in patients who had adhered to the protocol. The study was small and of short duration. Two randomised controlled trials of rivastigmine versus placebo reported falls as adverse events. Both reported lower proportions of falls occurring in the acetylcholinesterase inhibitor groups than in the placebo groups (seven [3%] of 211 vs nine [7%] of 123 patients; and 21 (6%) of 362 vs 11 (6%) of 179 patients), although in both studies the absolute numbers were small. One study reported that galantamine was associated with a decrease in falls, freezing, and gait domains of the Unifi ed Parkinson's Disease Rating Scale. Another trial stated that "increased number of falls" contributed to withdrawal of a participant.
Added value of this study
To our knowledge, this is the fi rst randomised controlled trial to examine the eff ect of rivastigmine on gait stability and falls in Parkinson's disease. Rivastigmine improved measures of gait stability and reduced fall frequency in people with Parkinson's disease without dementia. Rivastigmine is already licensed for Parkinson's disease dementia, hence its effi cacy to enhance cognition is established, along with its tolerability and safety profi le. Our trial design provides some insight into the mechanisms by which rivastigmine improves gait and reduces fall rates, and might inform future interventions and trial designs.
Implications of all available evidence
These fi ndings support the role for acetylcholinesterase inhibitors in ameliorating gait dysfunction and fall prevention in Parkinson's disease. These fi ndings need to be reproduced in a large phase 3 trial with falls as the primary outcome measure and that will collect evidence on cost-eff ectiveness.
Patients had to demonstrate the ability to walk 18 m without a walking aid and had to have reported at least one fall in the previous year; the best predictor of future falls. 3 Patients were excluded if they did not speak English; had an absolute contraindication to, or had previously taken, acetylcholinesterase inhibitors; or had any other neurological, visual, or orthopaedic problem that meaningfully interfered with gait. We excluded patients with dementia, classifi ed using the Movement Disorder Society Task Force defi nition of decreased cognition of suffi cient severity to impair daily life. 32 We recruited participants from community and hospital settings in the UK (mostly in southeast England 
Randomisation and masking
Patients were randomly assigned (1:1) to oral rivastigmine or placebo capsules matched to those for rivastigmine in colour and weight. We intended to randomise using a minimisation approach; however, during recruitment and while assignments remained blinded, it became apparent that a technical problem with the randomisation system (human error) had led to participants being randomised using simple randomisation. We therefore chose to continue with simple randomisation because the anticipated sample size (>100 people) would most likely result in balance between known and unknown confounders. Participants were enrolled and tested by an investigator who had no access to the randomisation sequence, which was computer generated by the Bristol Randomised Trials Collaboration (BRTC) clinical trials unit using a web-based program and accessed by the research team via a secure webpage. A treatment pack number was issued via a secure website that matched the number to a drug pack held in the pharmacy to ensure concealment of allocation. We assessed whether participants were aware of their treatment group status by asking them at the 32 week follow-up visit to guess which treatment they had received.
Procedures
A full description of the assessments used in the trial is in the published protocol. 31 Baseline measures of general health status and sociodemographics were recorded by EJH. We assessed gait and balance, cognition, mood, and fall risk factors at baseline (pre-treatment) and at the end of the 32 week treatment period. We measured occurrence of falls with use of monthly falls diaries, which patients posted monthly to the investigators. We telephoned participants every month to corroborate fall information, titrate medication, and to record adverse events. Our methods were consistent with guidelines from the Prevention of Falls Network Europe, 33 which recommend "prospective daily recording and a notifi cation system with a minimum of monthly reporting" and the use of telephone interviews for verifi cation.
For assessment of the primary endpoint, participants were asked at the baseline and 32 week visit to walk along a 22 m, fl at, outdoor, covered walkway while wearing a triaxial accelerometer (DynaPort Hybrid, McRoberts, Netherlands). Patients were assessed in the on-drug state in repect to their standard dopaminergic drugs. The middle 18 m, marked by external triggers, was used to assess steady state walking performance. We used three conditions: normal walking, simple dual task with phonemic verbal fl uency (walking while naming words beginning with a single letter), and complex dual task switching with phonemic verbal fl uency (walking while naming words, alternating between two letters of the alphabet). Each condition was done three times, yielding nine walks in total, to ensure accurate assessment of gait performance. Using a computergenerated random list generated by BRTC we randomly ordered the conditions to minimise fatigue and practice eff ects. Gait analysis used accepted standards known to be sensitive to both a diagnosis of Parkinson's disease 34 and predictive of falls. 35 Rivastigmine (or equivalent as placebo) dose was started at 3 mg per day (1·5 mg tablet taken twice a day) and was uptitrated in 3 mg per day (or placebo) increments every 4 weeks to a maximum of 12 mg per day at week 13 onwards. Participants were given suffi cient capsules of all four strengths (1·5 mg, 3 mg, 4·5 mg and 6 mg rivastigmine or matched placebo) for the study period and were advised on which to take by the trial team (overseen by EJH) via telephone. Identical titration was performed for those taking placebo to maintain masking. The highest tolerated dose was maintained for the following 16 week period, yielding a total treatment period of 32 weeks. Participants were instructed to downtitrate to the last tolerated dose or stop the drug, which was decided according to clinical judgment when unacceptable side-eff ects occurred.
Surveillance for adverse events took place over 12 months, which included the 4 months beyond the intervention period to detect any events with a prolonged latency. Patients were provided with a leafl et detailing potential side-eff ects and could telephone the study team to report adverse events at any time. Blinded researchers For more about DeNDRoN see https://www.crn.nihr. ac.uk/dementia established seriousness, causality, intensity, expectedness, and severity of adverse events according to established criteria 36 and events were coded post hoc using the MedDRA dictionary, version 17.1.
Outcomes
The primary outcome was diff erence in step time variability between the two groups at 32 weeks and adjusted for baseline age, cognition, step time variability, and number of falls in the previous year. Secondary outcomes were the rate per month of falls defi ned as an unexpected event in which participants come to rest on the ground, fl oor, or lower level, 33 and functional mobility through gait speed in each condition (time taken to walk the 18 m). Other pre-specifi ed secondary outcomes were fall risk (Physiological Profi le Assessment falls risk score); fear of falling (short-form 37 and quality of life (measured by EuroQol's EQ-5D-5L and described in the visual analogue score and index score, derived using Offi ce of Health Economics UK value set 38 ).
Statistical analysis
We had little evidence to guide the power calculation since no data were available on the eff ect of rivastigmine on step time variability. A sample size of 130 was chosen on the basis of an anticipated 30% drop-out rate, 39 resulting in about 90 patients (45 per arm). This sample size would enable a treatment eff ect diff erence of 0·6 standardised (Z score) units for the primary outcome measure to be detected with 80% power and at a two-sided 5% signifi cance level. This sample size was similar to that used in a study of patients without Parkinson's disease but with mild cognitive impairment. 40 Gait variability was assessed using the SD of step times. We established step time from consecutive heel strike peaks in the acceleration trace. We calculated the SD of step times for each walk and used the mean of these SDs across all three walks, for each condition, as the primary endpoint of step time variability in the statistical analysis. We specifi ed the SD of step times and not the SD of stride times because it includes assessment of within-stride gait asymmetry in people with Parkinson's disease and provides more data points, which enables more reliable measurement of gait variability (appendix). 41 The primary analysis was done in a modifi ed intentionto-treat population, whereby we included all patients except those who withdrew, did not attend assessment, or died. Secondary analyses were done in participants in the modifi ed intention-to-treat population from whom data were available. Adverse event and safety analyses were done in the full trial population.
When outcomes were positively skewed (primary outcome included) we log-transformed the outcome, hence the coeffi cients from our models represent the proportional change (geometric ratio means) in outcome between the treated and placebo groups. The percentage reduction was calculated by 100 -geometric ratio mean. When transformation could not achieve normality, we categorised data and used ordinal logistic regression models. We used multivariable linear models to adjust for a-priori specifi ed determinants of gait variability measured at baseline (centred around the mean if appropriate); age, cognitive function (MoCA), previous falls (ordinal variable 1, 2-3, 4-6, 7-19, ≥20) and baseline log step time variability.
For the primary outcome, we did pre-specifi ed subgroup analyses for age group, cognitive function (MoCA), and Parkinson's disease duration, measured as time in years from onset of fi rst motor symptom to enrolment, by fi tting interaction terms to the See Online for appendix multivariable regression models. We made no formal correction for multiple testing. We used negative binomial regression for the analysis of fall rates as recommended, 42 because these data are known to cluster within individuals and an initial exploratory model using Poisson regression confi rmed that the data were over-dispersed. We used the same covariates as for the primary outcome analysis for the falls analysis. Where data could not be transformed to meet the assumptions of normality it was categorised (appendix). We use descriptive statistics to report adverse events from all patients, irrespective of medication and protocol adherence. A planned sensitivity analysis of the primary outcome was done with use of multiple imputation for missing data. All analyses were done with Stata version 13.1.
We did not convene a data monitoring committee because rivastigmine is in widespread use. However, an independent advisor (a clinical academic) was appointed to review all serious adverse events (unblinded if necessary) and advise the trial team. The trial was registered with ISRCTN, 19880883; WHO universal trial number U1111-1124-0244.
Role of the funding source
The funder (Parkinson's UK) had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. Novartis provided feedback about the dosing of the trial drug, but had no other input into the design or implementation of the study and did not participate in preparing this manuscript for publication. The corresponding author had full access to all the data and had fi nal responsibility to submit for publication.
Results
Between Oct 4, 2012, to March 28, 2013, we enrolled 130 patients, randomly assigning 65 to the rivastigmine group and 65 to the placebo group (fi gure 1). Baseline demographic and clinical characteristics were similar between groups, although there were more women in the rivastigmine group and the daily levodopa equivalent dose was higher in the placebo group (table 1). Of the 130 participants enrolled, three died, four withdrew, and three were too unwell to attend the 32 week assessment. One additional participant provided some verbal outcome data via telephone.
We assessed 59 patients in the placebo group and 55 in the rivastigmine group for step time variability; some patients were excluded from certain conditions because they were unable to complete the walk or because of problems with the accelerometry data (fi gure 1).
Step time variability was 28% lower (geometric mean ratio 0·72, 95% CI 0·58-0·89; p=0·002) in the normal walking task and 21% lower (0·79, 0·62-0·99; p=0·045) during the simple dual task in those assigned to rivastigmine compared with those assigned to placebo (table 2) . The 19% improvement in step time variability shown in the rivastigmine group during the complex dual task was not signifi cant (0·81, 0·60-1·09; p=0·17). There was no evidence of any eff ect modifi cation with age, cognition, or disease duration in any of the three walking conditions (all interaction p>0·05), although we recognise that these analyses were probably underpowered to detect a diff erence. In a sensitivity analysis with multiple imputed datasets for missing data (appendix) the results for normal walking became more conservative (geometric mean ratio 0·77, 95% CI 0·61-0·97; 0·027) and the diff erence between the groups in the simple dual task was no longer signifi cant (0·84, 0·65-1·07; p=0·15).
One participant in the rivastigmine group had an extremely high number of falls (1122 falls during the treatment period) and so was removed from the analysis of fall rate. Median fall rate in the rivastigmine group (n=64; one outlier excluded) was 0·50 (IQR 0·14-0·89), compared with 1·14 (0·27-2·6) in the placebo group (n=65; fi gure 2). After adjustment for age, baseline cognition (MoCA score), falls in the previous year Step time variability (s) (quintiles 1, 2-3, 4-6, 7-19, ≥20), and baseline step time variability during normal walking, participants in the rivastigmine group had a reduction of 45% in the rate of falls per month (table 3) . We did two post-hoc sensitivity analyses to account for exclusion of the outlier from the calculation of fall rate. We repeated the negative binomial regression model but including the outlier, who was assigned the next highest value of falls (number of falls plus one of next highest participant in that group). The adjusted diff erence in fall rate remained signifi cant (incident rate ratio 0·58, 95% CI 0·58-0·85; p=0·005; appendix). Using multinomial logistic regression, fall rates were categorised as low, intermediate, high, or very high, with the outlier in the very high category (appendix). Treatment with rivastigmine was associated with a reduced chance of being in the high fall rate or very high fall rate categories compared with the low fall rate category (appendix). On visual inspection, fall rates increased over time in the placebo group, but not in the rivastigmine group (fi gure 3). Rivastigmine was associated with a small but signifi cant improvement in gait speed in all three task conditions, with the greatest eff ect seen in normal walking (table 3) . Improvements in controlled leaning balance were present in the rivastigmine group (more people in the rivastigmine group belonged to the low score group [good performance] vs medium and high score groups [poorer performance]; table 3). All other secondary outcomes-ie, fall risk, fear of falling, freezing of gait in the past month, cognition and mood measures, disease severity, levodopa requirement, and quality of life measures-did not diff er between patients assigned to rivastigmine and those assigned to placebo (table 3) .
At 32 week follow-up or withdrawal, 39 (60%) of 65 participants in the rivastigmine group versus 46 (71%) of 65 participants in the placebo group were still taking the study drug. Three participants in the rivastigmine group stopped for reasons not related to adverse events (participant choice, n=2; additional drug started that was contraindicated with rivastigmine, n=1); all other stoppages (n=23 in rivastigmine group, n=19 in placebo group) were due to adverse events. At 32 weeks, participants in the placebo group were taking a higher median treatment dose per day (10·0 mg, IQR 6·0-10·5) than were those in the rivastigmine group (6·3 mg, 2·7-8·7).
We did a post-hoc analysis to assess masking success using Bang's Blinding Index. 43 The null value of the Bang Blinding Index is 0, with a value greater than 0 representing failure in masking and a value lower than 0 suggesting that the failure in blinding is reversed. Bang's blinding index was 0·6 (95% CI 0·8-0·3) for the rivastigmine group and 0·2 (95% CI 0·4-0·0) for the placebo group, indicating that more participants in the rivastigmine group guessed their allocation correctly than would be expected by chance.
During the treatment period, 2184 adverse events occurred, of which 1875 were falls (1197 falls in placebo group, 678 falls in rivastigmine group). 27 adverse events were classifi ed as serious (14 in the rivastigmine group and 13 in the placebo group; appendix). Of the 14 serious adverse events that occurred in the rivastigmine group, only two were assessed as being probably or defi nitely related to the treatment, both of which were worsening of parkinsonism. About a third of participants in the rivastigmine group experienced nausea (n=20 [31%]; table 4), which was similar to the reported frequency of nausea with rivastigmine in a larger clinical trial. 39 Nearly Figure 2 : Crude fall rate by treatment group Box and whisker plot shows median (line) and IQR (box); upper and lower whiskers represent the 15th to 85th centiles. Values above and below whiskers plotted separately (dots), but we excluded one extreme outlier. 18 participants (nine in each group) had a fall rate of zero and were assigned an arbitrary value of 0·01 on the log scale; dots for these participants are superimposed. Normal walk † 0·064 s (0·114); 0·027 s (0·019-0·054) 0·043 s (0·044); 0·023 s (0·016-0·049) 0·83 (0·60-1·15) 0·72 (0·58-0·89) 0·076 p=0·002 28%
Simple cognitive task plus walk † 0·122 s (0·231); 0·060 s (0·034-0·114) 0·111 s (0·199); 0·042 s (0·025-0·145) 0·85 (0·59-1·23) 0·79 (0·62-0·99) 0·093 p=0·045 21%
Complex cognitive task plus walk 0·161 s (0·238); 0·078 s (0·040-0·162) 0·145 s (0·221); 0·065 s (0·031-0·167) 0·86 (0·58-1·27) 0·81 (0·60-1·09) 0·122 p=0·17 19%
Data for step time variability given in seconds (s) and are mean (SD); median (IQR). *Adjusted for centred age, centred baseline cognition (MoCA score), centred log baseline step time variability of condition, and previous falls categorised as (1, 2-3, 4-6, 7-19, ≥20). †n=58 for placebo group. GMR=Geometric mean ratio. Three deaths occurred; all were unrelated to the trial drug-one patient each died from known malignancy, peritonitis, and previously unknown pancreatic malignancy. No adverse events that we considered to be related to the study drug occurred between end of the treatment period and the 52 week follow-up.
Discussion
To our knowledge, this is the fi rst trial to show that rivastigmine can improve gait stability and might reduce falls in patients with Parkinson's disease, and has acceptable tolerability and safety consistent with previous work. Because we did not adjust for multiple testing, the benefi cial eff ect on step time variability for the simple cognitive task should be interpreted with caution and a sensitivity analysis with an imputed dataset rendered this association not signifi cant. Diff erent strategies have been trialled to reduce fall risk in Parkinson's disease. Consensus-based recom mendations to reduce fall risk were published in 2014 but with a small evidence base. 44 Acknowledging the multifactorial aetiology of falls, guidance advocates targeting interventions at age-specifi c and disease-specifi c risk factors. Early trials of physiotherapy based interventions were hampered by inadequate power and heterogeneity of the intervention delivered. However, trials of strength, balance, and cueing therapy in early disease 45 and of Tai chi 46 have shown signifi cant reductions in fall rates (69% and 67%, respectively). The eff ect of deep-brain stimulation on gait, balance, and falls has produced confl icting results. 47 Extrapolation of results from these studies is limited by the small sample sizes, diff erent targets, and the insuffi cient detail involved in reporting falls outcomes from the Unifi ed Parkinson's Disease Rating Scale (UPDRS) part 2 item. Acetylcholinesterase inhibitor treatment with donepezil was shown to reduce falls frequency in a cross-over trial of 23 patients. 48 Although this eff ect appears to be driven by individuals who fell most frequently, this result is congruent with our fi ndings and supports the potential role for acetylcholinesterase inhibitors in decreasing falls in Parkinson's disease.
The benefi t of rivastigmine treatment on falls is likely to have resulted from improvement in gait variability, velocity, and balance. This gain might or might not be mediated via improved cognition, specifi cally improved attention to compensate for impaired gait resulting from striatal dopaminergic loss, or via a direct eff ect on gait. 27, 30 Future analysis is needed to assess the mechanism of cognitive-gait interference, especially whether acetylcholinesterase inhibitor treatment ameliorates loss of attentional resource or whether it refocuses attentional priority to gait and movement control. 49 The apparent absence of signifi cant improvement in the secondary measures of cognitive and executive function could have resulted from insensitivity of the measurement instruments in our population, which was not cognitively impaired. Additionally, these fi ndings might have been a type 2 error because previous randomised controlled trials that have showed a benefi t at treating patients with Parkinson's disease dementia were much larger in size. 39 The high number of adverse events in both groups likely refl ects the high burden of comorbidity seen in our older cohort, coupled with the fact that patients were primed and screened monthly for adverse events. The observed profi le of adverse events is similar to that shown in previous reports and only a small proportion of the total events were likely to be related to the intervention. In future, administration of rivastigmine via patches, as is common in current clinical practice for Parkinson's disease dementia, might improve tolerability because use in Alzheimer's disease dementia is associated with lower rates of nausea and vomiting than with oral administration. 50 The occurrence of drug sideeff ects or positive outcomes for the actively treated group is likely to account for the observations that participants in this group were more likely to correctly guess their allocation than would be expected by chance. The strengths of this trial include its randomised placebo-controlled design, objective outcome measure, and high retention rate of participants. Because this was a phase 2 study, we choose a surrogate marker of fall risk, gait variability, because we were uncertain as to whether the trial would be suffi ciently powered to detect a diff erence in fall rate, a more commonly used clinical outcome. Despite our double-blind design, there was some evidence that participants in the treatment group might have guessed allocation group and this might have biased our results. Use of acetylcholinesterase inhibitors for gait and balance might not be eff ective for all patients with Parkinson's disease. In excluding those who were dependent on walking aids, we might have excluded people with more marked gait dysfunction who would have had potentially greater benefi t from the intervention. Alternatively, effi cacy might be attenuated by the greater cholinergic deaff erentation present in patients with more advanced disease. The single-site nature of the trial might also decrease the generalisability of these fi ndings. Future studies with larger sample sizes will allow analyses to identify subgroups of patients that will benefi t most from rivastigmine.
We believe it is now necessary to undertake a larger phase 3 randomised controlled trial with falls as the primary outcome and with a cost-eff ectiveness analysis before we can confi dently advise on the routine use of rivastigmine in the management of falls in patients with Parkinson's disease.
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